Wockhardt | Business Upturn

Latest Articles

Wockhardt submits NDA to US FDA for novel antibacterial Zidebactam-Cefepime

Corporates · Oct 1, 2025

blank

Wockhardt Q1 Results: Shares drop 3% as EBITDA falls 20.9% YoY Rs 72 crore, revenue flat at Rs 739

Stock Market · Aug 8, 2025

blank

Wockhardt shares jump 4% after exiting loss-making US generics business

Stock Market · Jul 14, 2025

blank

Wockhardt exits US generics business to focus on innovative portfolio

Corporates · Jul 11, 2025

blank

Wockhardt shares surge 10% as flagship antibiotic Zaynich demonstrates breakthrough clinical success

Stock Market · Jan 31, 2025

By Aditya Bhagchandani

blank

Wockhardt’s Zaynich achieves 96.8% clinical cure rate, sets new benchmark in Phase III global study

Corporates · Jan 31, 2025

By Aditya Bhagchandani

blank

Wockhardt’s Zaynich achieves 97% efficacy in treating resistant infections

Corporates · Jan 13, 2025

By Aditya Bhagchandani

blank

Wockhardt shares surge nearly 5% after CDSCO approval for revolutionary antibiotic Miqnaf

Stock Market · Jan 3, 2025

By Aditya Bhagchandani

blank

Wockhardt shares surge over 8% on successful Zaynich treatment for drug-resistant infections

Stock Market · Dec 16, 2024

By Aditya Bhagchandani

blank

Wockhardt shares jump 4% on Q2 FY25 results

Stock Market · Nov 13, 2024

blank

Wockhardt Q2 FY25 Results: Revenue up 7.43% YoY to Rs 809 crore, Net Loss widens to Rs 22 crore

Corporates · Nov 13, 2024

By Aditya Bhagchandani

blank

Wockhardt Q2 FY25 results: Stock drops 3% ahead of result announcement

Stock Market · Nov 13, 2024

blank

Wockhardt files Insulin Aspart injection with DCGI, reinforcing diabetes management commitment

Corporates · Oct 16, 2024

By Aditya Bhagchandani

blank

Wockhardt’s WCK 6777 earns Fast Track Designation from USFDA

Corporates · Oct 7, 2024

blank

Wockhardt founder Dr. Habil Khorakiwala honored with lifetime achievement award

Corporates · Sep 23, 2024

By Aditya Bhagchandani

Showing 15 of 17 articles